New blood marker reduces the risk of a false diagnosis of Alzheimer’s disease
Brief facts about the study
Alzheimer’s disease // clinical, prospective study // longitudinal // cohort study // peer-reviewed // in vivo // The study is published in The Lancet Neurology
Alzheimer's disease is characterised by the accumulation of two proteins in the brain: amyloid-beta and tau. Tau normally stabilises the structure of nerve cells, but in this disease the protein undergoes chemical changes and begins to form tangles in the neurons. This altered form is known as p-tau217 and can be measured in the blood.
However, the disease develops slowly over many years, and signs of Alzheimer’s in the brain can be detected in the blood up to 20 years before symptoms become apparent. A challenge inherent in using the new blood tests is determining whether the measurable biological changes are in fact the cause of the person’s symptoms or whether they are due to something else.
“The new blood tests that have recently come into use are effective at detecting early signs of Alzheimer’s – sometimes almost too early, as the disease has not yet fully developed and the symptoms may therefore be caused by another condition. More than 30 per cent of the elderly population show some signs of Alzheimer’s disease. We have therefore investigated a marker that is linked to a later stage of the disease, which may be more clinically useful”, says Niklas Mattsson-Carlgren.
Mattsson-Carlgren is a researcher at Lund University and works as a specialist physician at the memory clinic at Skåne University Hospital, and he led the research.
The study included 572 people who had sought medical care due to cognitive impairment and who had been included in the BioFinder2 study.
The researchers measured the individuals’ levels of the protein p-tau217 using advanced measurement techniques. Of the 350 people who had high levels of p-tau217, 341 of them (97 per cent) also had amyloid in the brain. The results show that high levels of p-tau217 are a very strong indicator of the presence of Alzheimer’s-related changes in the brain, a finding that has also been demonstrated in previous studies.
However, the blood test alone cannot determine how advanced the disease is. Only 199 of the 350 patients had already developed Alzheimer’s disease.
“A blood marker can sometimes produce a positive result in people who do not yet meet the criteria for the disease; these are known as false-positive results. This was the case for 43 per cent of those with high p-tau217 levels – they exhibited the changes but did not meet all the criteria for the disease,” says Niklas Mattsson-Carlgren.
The researchers also analysed another tau marker in the blood, eMTBR-tau243. The picture then became clearer: of the patients who tested positive for p-tau217, 194 (55 per cent) also had elevated levels of this marker. When researchers combined both markers, they were able to identify people with established Alzheimer’s disease with an accuracy rate of around 80 per cent. At the same time, the proportion of false-positive test results fell from 43 per cent to 16 per cent.
The results were validated in another group of American participants with similar cognitive difficulties.
“By combining blood markers, we can better identify which people have Alzheimer’s disease and which of them have such an advanced stage of the disease that it leads to symptoms.”
Furthermore, people who had both biomarkers in their blood experienced a more rapid decline in cognitive function over time and showed an increasing accumulation of tau protein in the brain.
“The new marker still requires analysis using advanced techniques such as mass spectrometry. The next step is to investigate whether the test can be simplified, and whether it can be used more widely, in primary care, for example,” says Niklas Mattsson-Carlgren.
The study has been published in The Lancet Neurology and is a collaboration between researchers at Lund University and Washington University.
END
Alzheimer’s disease // clinical, prospective study // longitudinal // cohort study // peer-reviewed // in vivo // The study is published in The Lancet Neurology
Alzheimer's disease is characterised by the accumulation of two proteins in the brain: amyloid-beta and tau. Tau normally stabilises the structure of nerve cells, but in this disease the protein undergoes chemical changes and begins to form tangles in the neurons. This altered form is known as p-tau217 and can be measured in the blood.
However, the disease develops slowly over many years, and signs of Alzheimer’s in the brain can be detected in the blood up to 20 years before symptoms become apparent. A challenge inherent in using the new blood tests is determining whether the measurable biological changes are in fact the cause of the person’s symptoms or whether they are due to something else.
“The new blood tests that have recently come into use are effective at detecting early signs of Alzheimer’s – sometimes almost too early, as the disease has not yet fully developed and the symptoms may therefore be caused by another condition. More than 30 per cent of the elderly population show some signs of Alzheimer’s disease. We have therefore investigated a marker that is linked to a later stage of the disease, which may be more clinically useful”, says Niklas Mattsson-Carlgren.
Mattsson-Carlgren is a researcher at Lund University and works as a specialist physician at the memory clinic at Skåne University Hospital, and he led the research.
The study included 572 people who had sought medical care due to cognitive impairment and who had been included in the BioFinder2 study.
The researchers measured the individuals’ levels of the protein p-tau217 using advanced measurement techniques. Of the 350 people who had high levels of p-tau217, 341 of them (97 per cent) also had amyloid in the brain. The results show that high levels of p-tau217 are a very strong indicator of the presence of Alzheimer’s-related changes in the brain, a finding that has also been demonstrated in previous studies.
However, the blood test alone cannot determine how advanced the disease is. Only 199 of the 350 patients had already developed Alzheimer’s disease.
“A blood marker can sometimes produce a positive result in people who do not yet meet the criteria for the disease; these are known as false-positive results. This was the case for 43 per cent of those with high p-tau217 levels – they exhibited the changes but did not meet all the criteria for the disease,” says Niklas Mattsson-Carlgren.
The researchers also analysed another tau marker in the blood, eMTBR-tau243. The picture then became clearer: of the patients who tested positive for p-tau217, 194 (55 per cent) also had elevated levels of this marker. When researchers combined both markers, they were able to identify people with established Alzheimer’s disease with an accuracy rate of around 80 per cent. At the same time, the proportion of false-positive test results fell from 43 per cent to 16 per cent.
The results were validated in another group of American participants with similar cognitive difficulties.
“By combining blood markers, we can better identify which people have Alzheimer’s disease and which of them have such an advanced stage of the disease that it leads to symptoms.”
Furthermore, people who had both biomarkers in their blood experienced a more rapid decline in cognitive function over time and showed an increasing accumulation of tau protein in the brain.
“The new marker still requires analysis using advanced techniques such as mass spectrometry. The next step is to investigate whether the test can be simplified, and whether it can be used more widely, in primary care, for example,” says Niklas Mattsson-Carlgren.
The study has been published in The Lancet Neurology and is a collaboration between researchers at Lund University and Washington University.
END